Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Rapidly responding to the needs of the evolving oncology landscape, AstraZeneca is focused on sourcing transformational programs and technologies, whilst nurturing mutually beneficial partnerships to deliver innovative treatment strategies to patients.
One-carbon Therapeutics has developed a novel method to target the vulnerability of cancer cells that interrupts a pathway used by tumor cells to maintain a high rate of proliferation.
Vaccination saves two to three million lives annually. GSK will continue delivering proven vaccines, expand their availability to populations in need, and create new vaccines to protect against endemic and emerging diseases. To those who possess novel technologies that can innovate vaccine creation, GSK ventures to be your partner of choice.
TiCARos, a South Korean biotech, aims to revolutionize cancer treatment with its advanced chimeric antigen receptor T cell (CAR-T) therapeutics and technologies that target both blood cancers and solid tumors.
Using three-dimensional tumor models and a next-generation technology platform, MEDiC Life Sciences aims to break boundaries in cancer drug development.
Pelago Bioscience, founded in 2013, aims to improve human health by helping its partners to discover and develop better therapeutics for difficult-to-drug targets.
Genialis has created ResponderID, a machine-learning platform that unravels complex biological signatures from patient data to deliver next-generation biomarkers for diagnostic and drug development.
With three decades of experience, over 200 client partnerships and several cell-line development platforms, Aragen Bioscience supports its global biopharma clients with end-to-end biologics development solutions and services.
GV20 Therapeutics’ platform decodes patients’ B cell responses with artificial intelligence to discover novel targets and antibodies simultaneously. Targets and antibodies are validated and de-risked computationally and experimentally.
The Korea Drug Development Fund and its ADCaptain Project are helping to bring novel antibody therapeutics through the development pipeline to patients in need.
Xentria is taking an innovative approach leveraging in vitro and pharmacokinetic models and the power of partnerships to co-develop accessible treatment options for patients with unmet needs.
Bioengineered Probiotic Yeast Medicines are oral, live therapeutics that express and secrete disease-targeting therapeutic molecules in situ for the treatment of gastrointestinal-related diseases. This synthetic biology approach offers advantages over conventional protein biologics and fulfils the dream of oral administration.
Perspix Biotech’s roPROTix platform combines artificial intelligence, robotics, and wet biology in a closed-loop feedback system for the discovery of next-generation multi-targeting biological therapeutics.
Captor Therapeutics is building a singular pipeline of both next-generation bifunctional degraders and molecular glues based on novel E3 ligases, leveraging academic expertise and industry experience in the United States and Europe, while utilizing significant public and private investment.
South Korean biotech Prazer Therapeutics is creating and validating a breakthrough drug discovery and development platform based on targeted protein degradation (TPD) technology to tackle previously undruggable targets in oncology, neuroscience and other therapeutic areas that are not readily addressable with existing TPD approaches.
InduPro is mapping the cell-surface proteome and designing novel binding proteins to bring cell-surface proteins together to manipulate signaling biology across a range of disease-relevant contexts.